Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.30 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3735475 | 1.00 | AAK1 (0.51) | AAK1PTPN1PTPN2SLC7A5EPHX2 | |
| SCHEMBL3733220 | 1.00 | AAK1 (0.51) | AAK1PTPN1PTPN2SLC7A5EPHX2 | |
| SCHEMBL3733222 | 0.85 | AAK1 (0.48) | AAK1PTPN1PTPN2SLC7A5EPHX2 | |
| SCHEMBL3750181 | 0.82 | AAK1 (0.58) | AAK1PTPN1PTPN2SLC7A5PPARG | |
| SCHEMBL3750184 | 0.82 | AAK1 (0.58) | AAK1PTPN1PTPN2SLC7A5PPARG | |
| SCHEMBL19088485 | 0.79 | AAK1 (0.57) | AAK1PTPN1PTPN2SLC7A5PPARG | |
| SCHEMBL18256471 | 0.79 | AAK1 (0.57) | AAK1PTPN1PTPN2SLC7A5PPARG | |
| SCHEMBL3735684 | 0.77 | POLB (0.38) | PTPN1PTPN2MLYCDITGA4ITGB7 | |
| SCHEMBL977220 | 0.77 | AAK1 (0.61) | AAK1SLC7A5PPARGITGA4ITGB7 | |
| SCHEMBL14450414 | 0.76 | PTPN1 (0.49) | PTPN1PTPN2EPHX2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829737-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090131374-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7504389-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080161592-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20060142250-A1 | Protein tyrosine phosphatase inhibitors and methods of use thereof | FALCON TECHNOLOGY PARTNERS L.P. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161592-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PPM1B, PTPN1, PTPN5 | AAK1 649/4885PTPN1 2/4885PTPN2 5/4885 |
| US-20060142250-A1 | Protein tyrosine phosphatase inhibitors and methods of use thereof | PPM1B, PTPN1, PTPN5 | AAK1 649/4885PTPN1 2/4885PTPN2 5/4885 |
| US-20090131374-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PPM1B, PTPN1, PTPN5 | AAK1 649/4885PTPN1 2/4885PTPN2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.